Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline (NCT06893835) | Clinical Trial Compass
Active — Not RecruitingPhase 4
Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline
Egypt132 participantsStarted 2024-12-01
Plain-language summary
Objective from this study to compare the clinical outcomes and safety between colistin and tigecycline for multi-drug resistant gram negative bacteria.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
Study will include
* adult patient (male, female)
* age from 18 to 70 years
* Patients admitted to intensive care unit in study period (six months) who received intravenous colistin or tigecycline as antimicrobial drug for treatment their MDR gram negative infection.
Exclusion criteria:
* Patient admitted to intensive care unit younger than 18 years or older than 70 years.
* Liver transplantation patients.
* Patients are chronic kidney disease (CKD on hemodialysis or baseline creatinine clearance (crcl) \< 10 ml/min (estimated by Cockcroft Gault equation).
* Patients received renal replacement therapy before or during admission.
* Patient is on any other nephrotoxic drug (vancomycin, aminoglycosides, NSAIDs, cyclosporine, amphotericin B, etc.).
* Pregnant and lactating women.
* Patients refused the consent of the study.
What they're measuring
1
comparison clinical success between colistin and tigecycline